Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Anti-human CCL24 monoclonal antibody (CM-101) - Part One
Anti-human CCL24 monoclonal antibody- Part One · 1 trial · 1 indication
Evaluation of the development of anti-drug antibodies (ADA) following repeated administrations of CM-101 -
| Arm | Type | Description |
|---|---|---|
| Anti-human CCL24 monoclonal antibody (CM-101) - study Part One | EXPERIMENTAL | Anti-human CCL24 monoclonal antibody (CM-101) NAFLD subjects that have normal liver functions - (Cohort 1: 2.5 mg/kg intravenously and Cohort 2: 5.0 mg/kg subcutaneously) |
| Placebo - Study Part One | PLACEBO_COMPARATOR | Placebo Comparator |
| Anti-human CCL24 monoclonal antibody (CM-101) - Study Part Two | EXPERIMENTAL | Anti-human CCL24 monoclonal antibody (CM-101) NAFLD/NASH patients with NAS \< 3 that are in general good health and have normal liver functions - 2.5 mg/kg intravenous infusion |
| Placebo - Study Part Two | PLACEBO_COMPARATOR | Placebo Comparator |
| Name | Type | Description |
|---|---|---|
| Anti-human CCL24 monoclonal antibody (CM-101) - Part One | DRUG | Anti-human CCL24 monoclonal antibody (CM-101) - Part One |
| Anti-human CCL24 monoclonal antibody (CM-101) - Part Two | DRUG | Anti-human CCL24 monoclonal antibody (CM-101) - Part Two |
| Placebo - Study Part One | DRUG | Placebo Comparator |
| Placebo - Study Part Two | DRUG | Placebo Comparator |
Inclusion Criteria: 1. Patients with US confirmation of NAFLD without evidence of NASH; 2. Patients with normal liver function tests (i.e. ALT, AST and ALP). 3. Patients in general good health expected for the preceding 6 months; 4. Women of childbearing potential must agree to use an approved form...
Anti-human CCL24 monoclonal antibody (CM-101) - Part One is an investigational monoclonal antibody developed by Chemomab Therapeutics Ltd. (ticker CMMB) for Nonalcoholic Fatty Liver Disease. It is also known as CM-101. The antibody targets human CCL24 and was studied in a Phase 1 clinical trial.
Anti-human CCL24 monoclonal antibody (CM-101) - Part One is being developed for the treatment of Nonalcoholic Fatty Liver Disease, a metabolic liver condition. It is an investigational therapy and has not been approved for any indication. The completed Phase 1 trial enrolled patients with NAFLD and NAFLD/NASH.
Anti-human CCL24 monoclonal antibody (CM-101) - Part One targets human CCL24, a chemokine also known as eotaxin-2. By binding to CCL24, the monoclonal antibody is designed to block its activity. This mechanism is being investigated in the context of Nonalcoholic Fatty Liver Disease.
Anti-human CCL24 monoclonal antibody (CM-101) - Part One is being developed by Chemomab Therapeutics Ltd., a biotechnology company whose ticker symbol is CMMB. Chemomab is responsible for the clinical development of CM-101 for Nonalcoholic Fatty Liver Disease.
Anti-human CCL24 monoclonal antibody (CM-101) - Part One is in Phase 1 development. A Phase 1 trial has been completed. The drug is investigational and has not been approved by the FDA or any regulatory agency for Nonalcoholic Fatty Liver Disease or any other indication.
Anti-human CCL24 monoclonal antibody (CM-101) - Part One has been studied in one completed Phase 1 clinical trial, NCT06044467, titled "The Study of Multiple Doses of CM-101 in Male and Female NAFLD and NAFLD/NASH Subjects." The trial enrolled 16 participants in Israel and was randomized, double-blind, and placebo-controlled.